Array BioPharma explained

Array BioPharma
Type:Subsidiary
Traded As:NASDAQ:
Industry:Oncology
Medication
Hq Location City:Boulder, Colorado
Hq Location Country:United States
Revenue:$173.8 million (2018)
Parent:Pfizer

Array BioPharma is an American clinical stage, pharmaceutical company that focuses on oncology medication headquartered in Boulder, Colorado. The company is currently a subsidiary of Pfizer after being acquired for $11 billion in 2019.

History

In 1998, the company was founded by Drs. Tony Piscopio, Kevin Koch, David Snitman, and K.C. Nicolaou.[1]

In November 2000, the company became a public company via an initial public offering.[2]

In June 2019, Pfizer acquired the company for approximately $11 billion.[3]

Discovery of FDA Approved Small Molecules

Notes and References

  1. Web site: Co-Founder Of Array BioPharma, Inc. To Lead New Korean Out-Sourcing Chemistry Company. 2020-07-28. BioSpace. en-US.
  2. News: Array IPO up 17% . . November 17, 2000.
  3. Web site: Pfizer acquires Array BioPharma, valued at $11.4 billion. 2020-07-29. Rappler. 18 June 2019 . en.